View this email in your browser
MedNess Business Special

MedNess: bite-size biopharma and medtech news
24th July, 2019
Subscribe here

MedNess is pleased to introduce our new series in the making
I-Cube
(Ideate-Innovate-Incubate)
This series will offer a glimpse into the world of startups working in the healthcare, pharmaceutical and biomedical domains. We aim to bring to the spotlight, the ideas and the people behind the innovation, in conversation with our new editor - Arundithi Ananthanarayanan
Arundithi Ananthanarayanan

Arundithi holds a PhD from Nanyang Technological University, Singapore where she worked on nanomaterial-based technologies for biomedical applications. She has a keen interest in entrepreneurship and is always excited to learn about new technologies and innovations. She also enjoys dancing, cooking and working towards educational causes.
If you are a sci-entrepreneur and would like to be featured in I-Cube, write to us at medness.newsletter@gmail.com
MedNess Business
BioPharma and MedTech

Medicxi raises €400M from Novartis and J&J for investments into European Biopharma

UK-based venture capital investment company, Medicxi, has raised €400M with Novartis and J&J being the strategic investors for Medixci III fund. This funding brings the total of over $1B raised by Medicxi in last three years. One of the biggest successes of Medicxi has been the acquisition of US-based cancer research biotech Impact Biomedicines by Celgene for $7B in 2018. The current funds will be invested into both the early-stage and the late-stage biopharma companies.

Gilead Sciences announces licensing of respiratory and herpes antiviral programs from Novartis

Gilead Sciences has announced a licensing agreement with Novartis for three preclinical antiviral programs for potential treatment for influenza, rhinovirus and herpes virus. According to the agreement, Novartis will receive and upfront payment and up to $291M in milestones payments and royalties on sales for an exclusive global rights to develop and commercialize novel small molecules against undisclosed targets. Gilead’s antiviral portfolio includes most widely used anti-viral medicines for influenza, HIV, Hepatitis B and Hepatitis C.
Jobs at Gilead Sciences

Water Street’s partnership results in first and only FDA-approved ready-to-use Insulin for IV fusion

Water Street Healthcare Partners’ strategic partnership with leading pharmaceutical company has received the FDA nod for the first and only ready-to-use Insulin Human in 0.9% sodium chloride for IV injections. The Insulin Human is developed by Water Street’s Celerity Pharmaceuticals and after FDA approval the ownership rights are transferred to its medical product company partner. The new approved product has extended shelf life of 30 days at room temperature and 24 months upon refrigeration.
Jobs at Water Street Partner

Mallinckrodt announces $5M equity investments besides $20M deal with Silence Therapeutics to develop and commercialize RNAi therapeutics

Mallinckrodt has announced collaboration with Silence Therapeutics for exclusive worldwide license for one preclinical molecule SLN500 that targets C3 protein in the complement pathway, with optional addition of two assets with different complement protein targets. Silence will receive an upfront payment of $20M with additional milestone payments including royalties on sales.

In parallel, Mallinckrodt via its subsidiary has also announced an equity investment of $5M in Silence Therapeutics. Mallinckrodt is subscribing for a total of 5,062,167 shares at a issue price of 79p per share at London Stock Exchange on July 24, 2019; which will represent 6.5% of total issued shares by Silence. As a consequence, Mallinckrodt has proposed to assign Steven Romano, Executive Vice President and CSO, as non-executive Director on Silence’s Board of Directors.

Jobs at Mallinckrodt
Click Here for more on  deals – M&A – Fund raising – Investments and more..
Editors' Desk
Richa Tewari, PhD
Oncology News
Esha Sehanobish, PhD
MedNess Plus
Mayur Vadhvani, PhD
Business News
Abhi Dey
Consulting Editor
Nisha Peter, PhD
Managing Editor
Ananda Ghosh, PhD
Founder
Share
Tweet
Forward
Subscribe
Disclaimer
The sponsors do not have any influence on the nature or kind of the news/analysis reported in Onco-this-Week. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of Medness. Examples of analysis performed within this article are only examples. They should not be utilized in real-world analytic products as they are based only on very limited and dated open source information. Assumptions made within the analysis are not reflective of the position of anyone volunteering or working for Medness. This blog is strictly for news and information. It does not provide medical advice, diagnosis or treatment nor investment suggestions. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Copyright © 2019 MedNess , All rights reserved.
You are receiving this MedNess Newsletter as a subscriber on the list.

Cover Image : Pixabay
Images : Twitter
Content Editors: Richa Tewari , Esha Sehanobish , Mayur Vadhvani and Abhinav Dey 
Concept and Design: Ananda Ghosh and Nisha Peter
Our mailing address is:
MedNess
2100 East County Line Rd
Ardmore, Pennsylvania 19003

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.